US 12,258,341 B2
IRAK degraders and uses thereof
Nello Mainolfi, Watertown, MA (US); Nan Ji, Watertown, MA (US); Arthur F. Kluge, Watertown, MA (US); Matthew M. Weiss, Watertown, MA (US); Yi Zhang, Watertown, MA (US); and Xiaozhang Zheng, Watertown, MA (US)
Assigned to Kymera Therapeutics, Inc., Watertown, MA (US)
Filed by Kymera Therapeutics, Inc., Watertown, MA (US)
Filed on Jul. 19, 2023, as Appl. No. 18/355,194.
Application 17/650,871 is a division of application No. 16/701,077, filed on Dec. 2, 2019, granted, now 11,352,350, issued on Jun. 7, 2022.
Application 18/355,194 is a continuation of application No. 17/650,871, filed on Feb. 14, 2022, granted, now 11,807,636.
Claims priority of provisional application 62/879,117, filed on Jul. 26, 2019.
Claims priority of provisional application 62/875,347, filed on Jul. 17, 2019.
Claims priority of provisional application 62/868,574, filed on Jun. 28, 2019.
Claims priority of provisional application 62/851,427, filed on May 22, 2019.
Claims priority of provisional application 62/831,007, filed on Apr. 8, 2019.
Claims priority of provisional application 62/826,743, filed on Mar. 29, 2019.
Claims priority of provisional application 62/793,992, filed on Jan. 18, 2019.
Claims priority of provisional application 62/788,460, filed on Jan. 4, 2019.
Claims priority of provisional application 62/774,051, filed on Nov. 30, 2018.
Prior Publication US 2024/0239777 A1, Jul. 18, 2024
Int. Cl. C07D 413/14 (2006.01); A61P 29/00 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 29/00 (2018.01)] 18 Claims
 
1. A compound selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.